Micar Innovation (Micar21) Bulgaria

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET.

Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Drug Discovery Collaborations
Headquartner in China
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 939.67KB)
Mr. DIMITAR DIMITROV
LinkedIn logo CEO 
Functionality

Mira Life Science Ventures United States

Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.

In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.

Mr. Mel Rothberg
Chairman 
Functionality

MSQ Ventures United States

MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients’ cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.
Mr. Estigarribia Marc
MD 

NurtureX United States

Strategy, Management and fundraising for genomic companies. Invest and help raise capital through private and public placements in the US, as well as guide company executives on Operational execution in the molecular diagnostics industry.

Company Size (Fulltime employees)
Please specify your partnering goal
Looking for new technologies and companies to invest and help with operational execution in the US
Headquartner in China
Medtech Category
Dr. Pankaj Singhal
LinkedIn logo President & CEO 
Functionality

Pleiogenix United States

Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial disease that Pleiogenix is targeting is alcoholic hepatitis (AH), with additional diseases to follow (COVID-19, Fibrosis, and NASH) . AH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. The global and US prevalence is 20-25%. The AH market is estimated to be $1.2 Billion in 2025, having a current annual growth rate of 6% (2019-2025). There are no approved efficacious therapeutics for the prevention or treatment of AH (dexamethasone reduces inflammation). The target patients for therapy include those with moderate and severe forms of AH. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic, and multiple metabolic clinical benefits. In patients suffering from AH, inflammation is severely increased. In animal models of NASH, increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical that exhibits multiple beneficial effects, in the context of AH.
Company Size (Fulltime employees)
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Fundraising (Seed Round)
Headquartner in China
Assets Information 1
PLG888|Orally-available, Phase 2A-ready drug candidate|alcoholic hepatitis|7 US patents; 1 each for Japan, Great Britain, France, Germany, and Australia
Assets Information 2
PLG888|ailable, Phase 2A-ready drug candidate|COVID-19; prevent /reduce cytokine storm|7 US patents; 1 each for Japan, Great Britain, France, Germany, and Australia
Assets Information 3
PLG888|Orally-available, Phase 2A-ready drug candidate|non-alcoholic steatohepatitis (NASH); Fibrosis diseases|7 US patents; 1 each for Japan, Great Britain, France, Germany, and Australia
Biotech/Pharma Asset Stage
Dr. Joseph Evans
CEO & President 
Functionality

Rius Medical UG (Haftungsbeschränkt) Germany

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!
Company Size (Fulltime employees)
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
Partnering goal is to improve life and generate substantial economic return
Headquartner in China
Mr. Denis Demarais
Founder and CEO 
Functionality

Roche China

Pharma and diagnostics
Website:
Roche.com
Headquartner in China
Ying Wang
BD director 
Philip Huang
VP 

Shanghai junshi biosciences Co.Ltd. China

Shanghai Junshi
丽君 陈
知识产权总监 

Shenzhen Runzelinke RNA Co.Ltd China

RNA(R&D)
Sheng Yang
Business Director